Aim: To verify the usefulness of FibroQ for predicting fibrosis in patients with chronic hepatitis C, compared with other noninvasive tests.
Methods: This retrospective cohort study included 237 consecutive patients with chronic hepatitis C who had undergone percutaneous liver biopsy before treatment. FibroQ, aspartate aminotransferase (AST)/alanine aminotransferase ratio (AAR), AST to platelet ratio index, cirrhosis discriminant score, age-platelet index (API), Pohl score, FIB-4 index, and Lok's model were calculated and compared.
Results: FibroQ, FIB-4, AAR, API and Lok's model results increased significantly as fibrosis advanced (analysis of variance test: P < 0.001). FibroQ trended to be superior in predicting significant fibrosis score in chronic hepatitis C compared with other noninvasive tests.
Conclusion: FibroQ is a simple and useful test for predicting significant fibrosis in patients with chronic hepatitis C.
Keywords: Alanine aminotransferase; Aspartate aminotransferase; Aspartate aminotransferase to platelet ratio index; Cirrhosis discriminant score; FIB-4 index; FibroQ; Liver fibrosis; Lok’s model; Noninvasive test; Pohl score.